Franc Gregori is a clinical pharmacist who worked with Boots, Eli Lilly, and Pfizer before moving into the City as an analyst. He has worked as a life sciences and healthcare analyst at various institutions, including Robert Fleming, BZW and BNP Paribas, covering everything from large pharma down to micro-cap healthcare service companies. He has been involved in a number of major transactions and has considerable experience of M&A, IPOs, and other advisory and corporate activities.

He gained his pharmaceutical qualifications at the Welsh School of Pharmacy and King’s College, London and has an MBA from Cranfield business school.

Lala Gregorek has broad experience as a life sciences analyst gained at Canaccord Adams and at Edison Investment Research, where she held various senior roles within the healthcare team. She has also worked in risk management at both Dresdner Kleinwort and Lehman Brothers, as a credit analyst focused on the financials sector.

She holds an MA in Biological Sciences (University of Oxford) and an MPhil in Bioscience Enterprise (University of Cambridge).

Philippa Gardner has over 15 years of experience as a healthcare sell side analyst, including at Lehman Brothers and Jefferies. During her time she mostly covered European drug development companies, from biotech through to large cap pharma, and has worked on a number of IPOs and secondary financings. She also spent a year working in healthcare strategic communications advisory.

She holds a Doctorate in Biochemical Engineering (EngD) and an MEng in Chemical with Biochemical Engineering, both from University College London.

Hans Bostrom has over 20 years experience as an equities analyst at leading firms including Goldman Sachs, BNP Paribas, and Credit Suisse. He has covered medtech and healthcare services companies of all sizes across the UK, Continental Europe, Middle East and Africa, and has been involved in numerous IPO and M&A transactions.

He holds an MSc in Financial Economics (Stockholm School of Economics), and was number two ranked for Medtech and Healthcare Services in the Institutional Investor annual survey from 2005-10.